<DOC>
	<DOCNO>NCT02393612</DOCNO>
	<brief_summary>Sarpogrelate hydrochloride , selective 5-HT2A antagonist , widely use anti-platelet agent treatment PAD . DP-R202 new Sarpogrelate hydrochloride product improve patient 's convenience disadvantage dosage regimen previous drug . The aim study compare efficacy safety DP-R202 Anplag® Tab patient PAD</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety DP-R202 Anplag Patients With Artery Occlusive Disease</brief_title>
	<detailed_description>1 . Design This clinical trial 12 week , multicenter , randomize , double-blind , parallel group , phase 3 study register patient total 25 institution appoint national clinical trial institution , conduct receive IRB ( institutional review board ) approval institution . Target patient age 20 year old male female lower limb peripheral artery occlusion patient fontaine stage II/III , low limb pain symptom like leg stretch numbing , low limb pain degree 40 mm evaluate VAS screening , ABI ( ankle-brachial index ) ≤0.9 stenosis rate &gt; 50 % , diagnose PAD voluntarily agree participate clinical study sign study consent form . In addition , exclusion criterion patient receive peripheral related surgery within 1 month clinical study participation , Fontaine stage 4 , NYHA class 3-4 , uncontrollable hypertension patient ( systolic BP ≥ 180 mmHg , diastolic BP ≥ 110 mmHg ) , patient history cerebrovascular disease ( cerebral infarction , cerebral hemorrhage etc . ) within 6 month prior clinical trial participation , patient uncontrollable diabetes ( HbA1c ≥ 9 % ) , patient renal insufficiency ( creatinine &gt; 3.0 mg/dL ) . Study subject meet subject criterion recruit total 151 subject ( study group : 75 subject , comparator group : 76 ) , among , 16 subject ( study group : 7 subject , comparator group : 9 subject ) dropouts therefore , total study subject complete study 135 subject ( study group : 68 subject , comparator group : 67 subject ) . Dropout reason 'clinical trial plan violation ' 3 subject ( comparator group : 3 subject ) , ' consent withdrawal ' 8 subject ( study group : 5 subject , comparator group : 3 subject ) , ' fail follow ' 1 subject ( comparator group : 1 subject ) , 'adverse event ' 3 subject ( study group : 1 subject , comparator group : 2 subject ) , ' reason ' 1 subject ( study group ) dropout due 'lack efficacy ' . Selected subject stratify 1:1 ratio randomly assign investigational product comparator Fontaine Stage II Fontaine Stage III use block randomization method double-blind apply investigator study subject . 2 . Administration Method Investigational product DP-R202 ( sarpogrelate hydrochloride 300 mg : DreamPharma , Inc. ) , comparator Anplag® Tab ( sarpogrelate hydrochloride 100 mg : Yuhan Corp. ) . Administration period subject 12 week , study group take investigational product , DP-R202 1 tab ( morning ) take placebo , Anplag® Tab 1 tab/once , 3 times/day , comparator group take investigational product , Anplag® Tab 1 tab/once , 3 times/day take DP-R202 , placebo 1 tab ( morning ) . Administration dosage test drug conduct fix dosage dosage fluctuation base subject 's condition perform . 3 . Efficacy Safety Assessment Parameter Subjects visit 4 , 8 , 12 week include baseline visit ( visit 2 ) 4 week interval ( total 4 time ) take efficacy quality life assessment . Variation low limb pain ( VAS ) compare baseline 12 week point primary efficacy Assessment parameter , variation lower limb pain ( VAS ) coldness 5-point scale compare baseline 4 , 8 week , ankle brachial pressure index ( ABI ) , ankle systolic pressure ( ASP ) , quality life assessment index ( SF-36 ) , Maximum Walking Distance ( MWD ) , Pain Free Walking Distance ( PFWD ) , investigator 's general assessment ( VAS ) 4 , 8 , 12 week secondary efficacy assessment parameter , efficacy measure . Pain coldness test measure use pain coldness felt subject 24 hour prior visit , MWD PFWD measure subject determine possible measure , ask record daily degree low limb pain every day baseline till end clinical trial subject record . Also , adverse even , laboratory test , vital sign , weight measurement conduct efficacy assessment . Physical test vital sign conduct screen visit , administration begin , 4 , 8 , 12 week administration urine pregnancy test laboratory test conduct screen visit 12 week administration . ECG test conduct screen visit , 4 , 8 , 12 week administration . Laboratory test criterion hematological test , blood chemical test , blood coagulation test urine test .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Sarpogrelate</mesh_term>
	<criteria>Lower limb pain degree 40 mm evaluate VAS screen ABI ( anklebrachial index ) ≤0.9 Patients peripheral relate surgery within 1 month clinical study participation Fontaine stage 4 , NYHA class 34</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>